Write to info@tradablepatterns.com for more info for any of the following Growth (Series B+) opportunities, or to be notified once a few Growth stage Fintech, Green Hydrogen plays begin their Series C and D in 2025
Malaysia’s 1st Biopharma Pre-Nasdaq IPO, Offering Plant-Based Supplement/Drug for Metabolic Disease (Equity)
- Plant extraction from SE Asia that treats metabolic diseases (e.g. obesity, diabetes, women’s diseases and cancer) w/o side effects
- European ESFA Novel Food approved and approved as food ingredient in US; testing as drug in Phase II clinic trials
- Flagship product has obtained patent for US, EU and Malaysia
- Product sold in Malaysia as dietary supplement already
- Signed distribution agreement w/ Korean distributor
- Applying for Korean food and hygiene license
- Est 2025 rev for South Korea: USD 1.3M
- Products seeking distribution in Middle East and Europe
- Raising USD 10M to complete clinical trials, regulatory clearance for 3rd party valuation USD 250-350M
UK Vaccine R&D and Production Company Uses Microneedle Patch to Administer Vaccines That Train T-Cells to Fight Pathogens (Equity)
- Vaccine targets beta-coronavirus, dengue fever, influenza and cancer w/o side effects of mRNA vaccines on human immune system
- Microneedle vaccine doesn’t require traditional oral intake or injection and doesn’t require refrigeration and cold chain transport
- Patch administered on skin, greatly improving vaccination rate at lower cost
- Vaccines against influenza, dengue fever and beta-coronavirus have completed 1st phase of human testing in Switzerland
- Only 2 vaccines globally for dengue (w/ Sanofi having largest mkt share but discontinuing dengue vaccine for children 2026) and Japan’s Takeda vaccine w/ limited availability
- Cancer vaccines under development
- Raising from cornerstone investors ahead of IPO
#2 Largest US Crypto Exchange (Secondary Equity)
- Among oldest crypto exchanges (founded 2011), w/ IPO planned for Q126
- 10M+ clients across 190+ countries (~29% mkt share in US), w/ USD 200B in quarterly trading volume
- Spot trading for 200 coins, margin trading (<= 5x leverage), crypto futures/derivatives, staking/yield services and insti service incl OTC
- Avg rev/user high @ ~ USD 2k/yr (vs Coinbase’s USD 825)
- Users trade more frequently or in lger size than avg Coinbase user
- Holds essentially crypto bank charter in Wyoming that may allow offering crypto friendly bank accounts where retail holding USD can convert to crypto
- 1st exchange to perform regular Proof of Reserves audits
- Regulated for futures in UK w/ FCA
- Operates leanly, raising USD 130M in VC capital (vs Coinbase’s USD 500M pre-IPO), w/ 2024 rev of USD 1.5B and USD 380M EBITDA
- Last known private valuation was USD 10B in mid-2021 during secondary share sale
BSE/NSE Indian Financial Holdco Preparing for US ADR Issuance (Equity)
- Indian financial holding BSE/NSE listco seeking US ADR issuance to expand
- Licensed for securities brokerage, insurance brokerage, wealth management, investment banking and lending w/ > 1M clients
- 2024 rev: USD 82M, 2024 net profit: USD 15M
- Current mkt value on BSE: USD 1B
- Shareholders: Indian UHNWIs
- Strong interest from US insti investors
